ULTRAGENYX PHARMACEUTICAL INC. Earnings Per Share (Basic)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Earnings Per Share (Basic) of -$0.90 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.90.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic for the quarter ending 2026-03-31 was -$1.84.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic for the quarter ending 2025-09-30 was -$1.81.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic for the quarter ending 2025-06-30 was -$1.17.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic for fiscal 2025 was -$5.83.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic for fiscal 2024 was -$6.29.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic for fiscal 2023 was -$8.25.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic for fiscal 2022 was -$10.12.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.90 10-Q · filed 2026-08-05 | -$2.73 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$1.84 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$5.83 10-K · filed 2026-02-18 | |||
| 2025-09-30 | -$1.81 10-Q · filed 2025-11-05 | -$4.55 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | -$1.17 10-Q · filed 2026-08-05 | -$2.73 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | -$1.57 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$6.29 10-K · filed 2026-02-18 | |||
| 2024-09-30 | -$1.40 10-Q · filed 2025-11-05 | -$4.91 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | -$1.52 10-Q · filed 2025-08-06 | -$3.54 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$2.03 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$8.25 10-K · filed 2026-02-18 | |||
| 2023-09-30 | -$2.23 10-Q · filed 2024-11-06 | -$6.81 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | -$2.25 10-Q · filed 2024-08-02 | -$4.58 10-Q · filed 2024-08-02 | ||
| 2023-03-31 | -$2.33 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | -$10.12 10-K · filed 2025-02-19 | |||
| 2022-09-30 | -$3.50 10-Q · filed 2023-11-03 | -$7.96 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | -$2.26 10-Q · filed 2023-08-04 | -$4.45 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | -$2.19 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | -$6.70 10-K · filed 2024-02-21 | |||
| 2021-09-30 | -$1.08 10-Q · filed 2022-11-03 | -$4.91 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$1.81 10-Q · filed 2021-08-03 | -$3.84 10-Q · filed 2021-08-03 | ||
| 2020-12-31 | -$0.37 10-K · filed 2021-02-12 | -$3.07 10-K · filed 2023-02-17 | ||
| 2020-09-30 | -$1.13 10-K · filed 2021-02-12 | |||
| 2020-06-30 | $0.42 10-Q · filed 2021-08-03 | -$1.59 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | -$2.05 10-K · filed 2021-02-12 | |||
| 2019-06-30 | -$1.72 10-Q · filed 2020-07-30 | -$3.54 10-Q · filed 2020-07-30 | ||
| 2019-03-31 | -$1.82 10-Q · filed 2019-05-07 | |||
| 2018-12-31 | -$1.73 10-K · filed 2020-02-14 | |||
| 2018-09-30 | -$1.74 10-K · filed 2020-02-14 | |||
| 2018-06-30 | -$1.06 10-K · filed 2020-02-14 | |||
| 2018-03-31 | $0.63 10-K · filed 2020-02-14 | |||
| 2017-03-31 | -$1.63 10-Q · filed 2018-05-08 | |||
| 2015-12-31 | -$3.96 derived: net income ÷ weighted average shares · filed 2017-02-17 | |||
| 2015-06-30 | -$0.83 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$1.46 derived: net income ÷ weighted average shares · filed 2015-08-14 | -$2.00 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$2.51 derived: net income ÷ weighted average shares · filed 2017-02-17 |
| 2015-03-31 | -$0.63 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$1.16 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$1.66 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$2.12 derived: net income ÷ weighted average shares · filed 2017-02-17 |
| 2014-12-31 | -$0.52 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$1.03 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$1.48 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$2.25 derived: net income ÷ weighted average shares · filed 2017-02-17 |
| 2014-09-30 | -$0.50 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$0.95 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$1.73 derived: net income ÷ weighted average shares · filed 2015-11-10 | -$3.06 derived: net income ÷ weighted average shares · filed 2016-02-26 |
| 2014-06-30 | -$0.45 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$1.25 derived: net income ÷ weighted average shares · filed 2015-08-14 | -$2.75 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$4.29 derived: net income ÷ weighted average shares · filed 2016-02-26 |
| 2014-03-31 | -$0.85 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$2.93 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$5.15 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$7.46 derived: net income ÷ weighted average shares · filed 2016-02-26 |
| 2013-12-31 | -$4.98 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$8.48 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$11.61 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$14.03 derived: net income ÷ weighted average shares · filed 2016-02-26 |
| 2013-09-30 | -$3.48 derived: net income ÷ weighted average shares · filed 2015-03-27 | -$6.57 derived: net income ÷ weighted average shares · filed 2015-03-27 | -$8.96 derived: net income ÷ weighted average shares · filed 2014-11-10 | |
| 2013-06-30 | -$3.09 derived: net income ÷ weighted average shares · filed 2015-03-27 | -$5.47 derived: net income ÷ weighted average shares · filed 2014-08-11 | ||
| 2013-03-31 | -$2.37 derived: net income ÷ weighted average shares · filed 2015-03-27 | |||
| 2012-12-31 | -$6.27 derived: net income ÷ weighted average shares · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |